-
Views
-
Cite
Cite
Infigratinib Phosphate, American Journal of Health-System Pharmacy, Volume 78, Issue 19, 1 October 2021, Pages 1748–1751, https://doi.org/10.1093/ajhp/zxab266
- Share Icon Share
Extract
Infigratinib phosphate is an antineoplastic agent.
Class: 10:00 • Antineoplastic Agents (AHFS primary)
Brands: Truseltiq®
Uses
Infigratinib phosphate has the following uses:
...
Dosage and Administration
General
Infigratinib phosphate is available in the following dosage form(s) and strength(s): Capsules: 25 mg and 100 mg; provided in 50-, 75-, 100-, and 125-mg dose packs.
Dosage
It isessentialthat the manufacturer’s labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:
Adults
Dosage and Administration
...
Cautions
Contraindications
None.
Warnings/Precautions
Ocular Toxicity
Retinal Pigment Epithelial Detachment (RPED)
Infigratinib phosphate can cause RPED, which may cause symptoms such as blurred vision.
Among 351 patients who received infigratinib phosphate across clinical trials where ophthalmologic monitoring did not routinely include optical coherence tomography (OCT), RPED occurred in 11% of patients, including patients with asymptomatic RPED. The median time to first onset of RPED was 26 days. RPED led to dose interruption/reduction of infigratinib phosphate in 3.4% of patients, and permanent discontinuation in 0.6% of patients.
Comments